GW Pharmaceuticals' Epidyolex (cannabidiol) Receives EC's Approval for the Treatment of Seizures Associated with Tuberous Sclerosis Complex
Shots:
- The approval is based on P-III study evaluating cannabidiol (25 mg/kg/day) vs PBO in patients aged ≥2yrs. as an adjunctive treatment of seizures associated with TSC
- The study met its 1EPs i.e reduction in seizure frequency (49% vs 27%). The 2EPs supports the effects on 1EPs and safety profile was consistent with findings from previous studies with no new safety risks were identified
- The EC has approved the Type II variation application for Epidyolex and marks the third indication in EU with the expanded launch across Europe. The EC decision is valid in all 27 countries
Ref: Business Wire | Image: Benzinga
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com